Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Nov 9 - Nov 14
The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults, part 3: the clinical guidelines
Key published studies include: Teichman et al., 2006 (JCEM): Dose-dependent GH and IGF-1 elevation with CJC-1295 DAC in healthy adults Raun et al., 1998 (Eur J Endocrinol): Ipamorelin demonstrated selective GH release without cortisol/prolactin elevation Johansen et al., 1999: Phase I/II Ipamorelin trial showed dose-response relationship with no significant adverse effects Bowers et al., 2004: Foundational research on GHRH/GHRP synergistic GH release mechanisms Neither CJC-1295 nor Ipamorelin has completed Phase 3 clinical trials
For the remainder of this article, when we refer to CJC-1295, we are primarily discussing the short-acting Mod GRF 1-29, as it's the more commonly used variant in modern research protocols, especially when combined with a GHRP like Ipamorelin in blends like our CJC1295 Ipamorelin 5MG 5MG stack
Ipamorelin is studied as a selective ghrelin mimetic it binds the growth-hormone-secretagogue receptor (GHSR-1a), the same receptor the hunger hormone ghrelin uses, and in research settings appears to stimulate GH release with relatively limited effect on other hormones such as cortisol, prolactin, and ACTH
Made of three amino acids (glutamine, glycine, and cysteine), it defends against free radicals, supports your immune system, and helps detoxify your body
US$ 20.56
US$ 24.79
US$ 20.05
US$ 26.39
US$ 24.23
US$ 26.12
US$ 21.14
